Quick-Med wound care tech to enter US trials
This article was originally published in Clinica
US company Quick-Med Technologies and the University of Florida are to begin clinical trials of their jointly-developed next-generation wound care technology, Nimbus. Shands Hospital, Florida, will be the site for the trials later this year. The products kills bacteria but does not allow the active microbicide to detach and enter the wound. This means that the risk of antibacterial resistance is lower, said Gainesville, Florida-based Quick-Med. The technology is effective against antibiotic-resistant strains of bacteria, such as MRSA and VRE, it added.
You may also be interested in...
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.